Back to Authors

Reid–Lombardo, Kaye M.

Mayo Clinic

Divisions of Gastroenterologic and General Surgery and

Citations 3

Clinical Characteristics and Overall Survival in Patients with Anaplastic Pancreatic Cancer
Arun, Janani S., Zhang, Lizhi , Farnell, Michael B., Reid–Lombardo, Kaye M., Clark, Clancy J. , Graham, Rondell P.

The American Surgeon™ | June 17, 2020 | Volume: 80 | Issue: 2 | Pages: 117-123

10.1177/000313481408000218 Get It

Anaplastic pancreatic cancer (APC) is a rare undifferentiated variant of pancreatic ductal adenocarcinoma with poor overall survival (OS). The aim of this study was to evaluate the clinical outcomes of APC compared with differentiated pancreatic ductal adenocarcinoma. We conducted a retrospective review of all patients treated at the Mayo Clinic with pathologically confirmed APC from 1987 to 2011. After matching with control subjects with pancreatic ductal adenocarcinoma, OS was evaluated using Kaplan-Meier estimates and log-rank test. Sixteen patients were identified with APC (56.3% male, median age 57 years). Ten patients underwent exploration of whom eight underwent pancreatectomy. Perioperative morbidity was 60 per cent with no mortality. The median OS was 12.8 months. However, patients with APC who underwent resection had longer OS compared with those who were not resected, 34.1 versus 3.3 months ( P = 0.001). After matching age, sex, tumor stage, and year of operation, the median OS was similar between patients with APC and those with ductal adenocarcinoma treated with pancreatic resection, 44.1 versus 39.9 months, ( P = 0.763). Overall survival for APC is poor; however, when resected, survival is similar to differentiated pancreatic ductal adenocarcinoma.
Does Gastric Resection Have a Role in the Management of Severe Postfundoplication Gastric Dysfunction?
Sarr, Michael G. , Arora, Amindra S., Nichols, Francis C., Reid–Lombardo, Kaye M., Clark, Clancy J.

World Journal of Surgery | June 29, 2011 | Volume: 35 | Issue: 9 | Pages: 2045-2050

10.1007/s00268-011-1173-9 Get It

AbstractBackgroundBloating, flatulence, early satiety, and dysphagia resolve in more than 90% of patients early after fundoplication. Gastric dysfunction can persist, however, and a small number of patients develop severe gastric dysfunction (gastroparesis). Management of gastroparesis after antireflux procedures is generally conservative, but gastroparesis can become refractory to medical therapy. The aim of this study was to assess the role of gastric resection in the management of the unusual patient with severe postfundoplication gastric dysfunction.MethodsFrom January 1990 to October 2010, a total of 5,129 gastric resections were performed at our institution. From this cohort, we identified nine patients with postfundoplication gastric dysfunction managed with gastric resection. Clinical records were reviewed retrospectively for preoperative evaluation, perioperative course, and long‐term outcomes.ResultsOver 20 years, nine patients were treated with gastric resection for debilitating gastric dysfunction after antireflux surgery. Seven of the nine patients were female; the median preoperative body mass index was 25 kg/m2 (18–31 kg/m2). Median follow‐up was 23 months (1–97 months). Preoperatively, five patients required enteral feeding. Postoperatively, although there were no deaths, one patient required operative drainage of a subphrenic abscess, one developed temporary respiratory failure, and one was readmitted for partial small bowel obstruction. Six of the nine patients maintain their nutrition orally, but three are maintained with enteral nutrition. Only two patients are subjectively asymptomatic.ConclusionsOutcomes after gastric resection for postfundoplication gastric dysfunction are poor, with three of the nine patients requiring supplemental nutrition and seven of the nine having persistent symptoms.
Inflammation-Related Gene Variants as Risk Factors for Pancreatic Cancer
Reid–Lombardo, Kaye M., Bamlet, William R. , Cunningham, Julie M. , Sarr, Michael G., Petersen, Gloria M. , Fridley, Brooke L. , Bamlet, William R

Cancer Epidemiology, Biomarkers & Prevention | June 7, 2011 | Volume: 20 | Issue: 6 | Pages: 1251-1254

10.1158/1055-9965.epi-11-0264 Get It

Abstract Background: Recent reports support an association between chronic inflammation and progression to pancreatic cancer (PC). Methods: This case–control, candidate gene association study evaluated 1,354 Caucasian patients with pancreatic ductal adenocarcinoma and 1,189 healthy Caucasian controls. We genotyped 1,538 single nucleotide polymorphism (SNP) in 102 genes from inflammatory pathways involving NF-κB. Primary tests of association assumed a multiplicative (log-additive) genotype effect; secondary analyses examined dominant, additive, and recessive SNP effects. Results: After adjusting for known risk factors for PC, single SNP analysis revealed an association between four SNPs in NOS1 and one in the CD101 gene with PC risk. These results, however, were not replicated in a PC case–control and cohort population. Conclusion:NOS1 and CD101 may be associated with a risk of PC; however, these findings did not replicate in other PC populations. Future research is needed into the possible role of NOS1 and CD101 for PC. Impact: This research shows a lack of association between genetic variation in 102 inflammation-related genes and PC. Future research is needed into the possible role of other inflammation-related genes and PC risk. Cancer Epidemiol Biomarkers Prev; 20(6); 1251–4. ©2011 AACR.